KPTI / Karyopharm Therapeutics Inc. - Depositi SEC, Relazione annuale, dichiarazione di delega

Filing Fee Table

Calculation of Filing Fee Tables S-8 Karyopharm Therapeutics Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, $0.0001 par value per share Other 450,000 $ 4.01 $ 1,804,500.00 0.0001531 $ 276.27 Total O

As filed with the Securities and Exchange Commission on August 11, 2025

S-8 As filed with the Securities and Exchange Commission on August 11, 2025 Registration No.

Side Letter Amendment to License Agreement, dated June 30, 2025, by and between Antengene Therapeutics Limited and the Registrant

Exhibit 10.1 June 30, 2025 Karyopharm Therapeutics Inc. Attention: Chief Executive Officer 85 Wells Avenue, Suite 210 Antengene Therapeutics Limited Attention: Chief Executive Officer Suite 1209, West Zhongshan Road 1065 Shanghai, China 200051 Re: License Agreement Reference is made to the License Agreement (as such agreement may be modified from time to time in accordance with its terms, the “Lic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 11, 2025 Karyopharm Therapeu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 11, 2025 Karyopharm Therapeutics Inc.

Karyopharm Reports Second Quarter 2025 Financial Results and Highlights Recent Company Progress – New Patient Screening for Phase 3 SENTRY Trial in Myelofibrosis Expected to Close This Week; Top-Line Results Anticipated in March 2026 – – Total Revenu

Exhibit 99.1 Karyopharm Reports Second Quarter 2025 Financial Results and Highlights Recent Company Progress – New Patient Screening for Phase 3 SENTRY Trial in Myelofibrosis Expected to Close This Week; Top-Line Results Anticipated in March 2026 – – Total Revenue was $37.9 Million; U.S. XPOVIO® (selinexor) Net Product Revenue was $29.7 Million, up 6% compared to Second Quarter of 2024 – – Reaffir

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 11, 2025 Karyopharm Therapeuti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 11, 2025 Karyopharm Therapeutics Inc.

Confidential Investor Presentation July 2025 ©2025 KARYOPHARM THERAPEUTICS INC. | CONFIDENTIAL & PROPRIETARY

Confidential Investor Presentation July 2025 ©2025 KARYOPHARM THERAPEUTICS INC. | CONFIDENTIAL & PROPRIETARY Forward-Looking Statements and Disclaimers 2 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements with respect to the possible achievement of Karyopharm’s disco

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 28, 2025 Karyopharm Therapeutic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 28, 2025 Karyopharm Therapeutics Inc.

Amendment No. 3 to License Agreement, dated March 4, 2025, by and between the Registrant and Berlin-Chemie AG

Exhibit 10.2 AMENDMENT NO. 3 TO LICENSE AGREEMENT BY AND BETWEEN KARYOPHARM THERAPEUTICS INC. AND BERLIN-CHEMIE AG THIS AMENDMENT NO. 3 (the “Amendment”) is made and entered into as of March 4, 2025 (the “Amendment Effective Date”), by and between Karyopharm Therapeutics Inc., a corporation organized and existing under the law of Delaware and having its principal place of business at 85 Wells Ave.

Karyopharm Reports First Quarter 2025 Financial Results and Announces New Data in Myelofibrosis that Further Suggests Selinexor May Lead to Meaningful Spleen Volume Reduction, Symptom Improvement, Hemoglobin Stabilization and Disease Modification – N

Exhibit 99.1 Karyopharm Reports First Quarter 2025 Financial Results and Announces New Data in Myelofibrosis that Further Suggests Selinexor May Lead to Meaningful Spleen Volume Reduction, Symptom Improvement, Hemoglobin Stabilization and Disease Modification – New Randomized Phase 2 Monotherapy Data from XPORT-MF-035 Trial in a Hard-to-Treat Patient Population Further Strengthens Conviction in Se

Restated Certificate of Incorporation of the Registrant, as amended

Exhibit 3.1 RESTATED CERTIFICATE OF INCORPORATION OF KARYOPHARM THERAPEUTICS INC. (originally incorporated on December 22, 2008) FIRST: The name of the Corporation is Karyopharm Therapeutics Inc. (the “Corporation”). SECOND: The address of the Corporation’s registered office in the State of Delaware is Corporation Trust Center, 1209 Orange Street, in the City of Wilmington, County of New Castle, 1

Non-Employee Director Compensation Policy

Exhibit 10.1 KARYOPHARM THERAPEUTICS INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Non-Employee Director Compensation Policy (this “Policy”) of Karyopharm Therapeutics Inc. (the “Company”) is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors and reflect the substantial time commitment necessary

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 12, 2025 Karyopharm Therapeutics Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14

Certificate of Amendment of Restated Certificate of Incorporation of Karyopharm Therapeutics Inc.

Exhibit 3.1 CERTIFICATE OF AMENDMENT OF RESTATED CERTIFICATE OF INCORPORATION OF Karyopharm Therapeutics Inc. (Pursuant to Section 242 of the General Corporation Law of the State of Delaware (the “DGCL”)) Karyopharm Therapeutics Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the DGCL, does hereby certify as follows: FIRST: A resolution was d

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 24, 2025 Karyopharm Therap

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 24, 2025 Karyopharm Therapeutics Inc.

Insider Trading Policy

Exhibit 19.1 KARYOPHARM THERAPEUTICS INC. Insider Trading Policy Most Recently Approved by the Board of Directors on February 7, 2025 1. BACKGROUND AND PURPOSE 1.1 Why Have We Adopted This Policy? The federal securities laws prohibit any member of the Board of Directors (a “Director”), officer (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934 (the “Exchange Act”), an “executiv

Subsidiaries of the Registrant

Exhibit 21.1 Subsidiaries of Karyopharm Therapeutics Inc. Name Jurisdiction of Incorporation or Organization Karyopharm Europe GmbH Germany Karyopharm Israel Ltd. Israel

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-3616

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 19, 2025 Karyopharm Therapeutics Inc.

Description of Securities Registered under Section 12 of the Exchange Act

Exhibit 4.2 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT The following description of the common stock, $0.0001 par value per share (the “Common Stock”), of Karyopharm Therapeutics Inc. (“us,” “our,” “we” or the “Company”), which is the only security of the Company registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), summ

Karyopharm Reports Fourth Quarter and Full Year 2024 Financial Results, Announces Update to Phase 3 XPORT-EC-042 Trial and Highlights Recent Company Progress – Total Revenue of $145 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $113 Mil

Exhibit 99.1 Karyopharm Reports Fourth Quarter and Full Year 2024 Financial Results, Announces Update to Phase 3 XPORT-EC-042 Trial and Highlights Recent Company Progress – Total Revenue of $145 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $113 Million for Full Year 2024 – – Top-Line Data Readout from Phase 3 SENTRY Trial Evaluating Selinexor in Combination with Ruxolitinib in Patie

Restated Certificate of Incorporation of the Registrant, as amended

Exhibit 3.1 RESTATED CERTIFICATE OF INCORPORATION OF KARYOPHARM THERAPEUTICS INC. (originally incorporated on December 22, 2008) FIRST: The name of the Corporation is Karyopharm Therapeutics Inc. (the “Corporation”). SECOND: The address of the Corporation’s registered office in the State of Delaware is Corporation Trust Center, 1209 Orange Street, in the City of Wilmington, County of New Castle, 1

JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k)

EXHIBIT 99.1 JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The unders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 27, 2025 Karyopharm Therape

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 27, 2025 Karyopharm Therapeutics Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 30, 2025 Karyopharm Therape

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 30, 2025 Karyopharm Therapeutics Inc.

Karyopharm Announces Preliminary Unaudited 2024 Revenue and 2025 Objectives – Opportunity to Define a New Myelofibrosis Treatment Paradigm with Top-Line Data Readout from Phase 3 SENTRY Trial Evaluating Selinexor in Combination with Ruxolitinib in Pa

Exhibit 99.1 Karyopharm Announces Preliminary Unaudited 2024 Revenue and 2025 Objectives – Opportunity to Define a New Myelofibrosis Treatment Paradigm with Top-Line Data Readout from Phase 3 SENTRY Trial Evaluating Selinexor in Combination with Ruxolitinib in Patients with JAKi-Naïve Myelofibrosis Anticipated in 2H 2025; Company On Track to Complete Enrollment in 1H 2025 – – Recently Announced Ke

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 13, 2025 Karyopharm Therapeutics Inc.

Offer Letter, dated as of December 19, 2024, between the Registrant and Lori Macomber (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K (File No. 001-36167) filed with the Commission on January 2, 2025)

Exhibit 10.1 85 Wells Ave., Suite 210 | Newton, MA 02459 December 18, 2024 Lori Macomber Dear Lori, I am pleased to offer you the position of Executive Vice President, Chief Financial Officer and Treasurer with Karyopharm Therapeutics Inc. (the "Company"), reporting directly to Richard Paulson. This is an important position in the Company, and I know it will be a challenging and exciting one. We a

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 2, 2025 Karyopharm Therapeutics Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14

Karyopharm Therapeutics Provides Endometrial Cancer Program Update

EX-99.1 Exhibit 99.1 BELIEVERS IN THE EXTRAORDINARY Karyopharm Therapeutics Provides Endometrial Cancer Program Update NEWTON, Mass. – December 3, 2024 – Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it is in discussions and has an upcoming meeting with the U.S. Food and Drug Administration (FDA) regar

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 3, 2024 Karyopharm Therape

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 3, 2024 Karyopharm Therapeutics Inc.

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 20, 2024 Karyopharm Therapeutics Inc.

KPTI / Karyopharm Therapeutics Inc. / Avidity Partners Management LP Passive Investment

SC 13G/A 1 d1153051613g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Karyopharm Therapeutics Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 48576U106 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropr

Sixth Amendment to Lease, dated as of November 5, 2024 by and between the Registrant and TCD 234 MA WELLS PROPERTY LLC (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K (File No. 001-36167) filed with the Commission on November 8, 2024)

Exhibit 10.1 SIXTH AMENDMENT TO LEASE This SIXTH AMENDMENT TO LEASE (this “Sixth Amendment”) is dated as of November 5, 2024 (the “Sixth Amendment Effective Date”) and is hereby entered into by and between TCD 234 MA WELLS PROPERTY LLC (“Landlord”), a Delaware limited liability company, and KARYOPHARM THERAPEUTICS INC. (“Tenant”), a Delaware corporation. RECITALS WHEREAS, Landlord, as successor-in

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 5, 2024 Karyopharm Therape

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 5, 2024 Karyopharm Therapeutics Inc.

As filed with the Securities and Exchange Commission on November 5, 2024

As filed with the Securities and Exchange Commission on November 5, 2024 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe

Amendment No. 3 to the 2022 Inducement Stock Incentive Plan

Exhibit 99.4 AMENDMENT NO. 3 TO 2022 INDUCEMENT STOCK INCENTIVE PLAN OF KARYOPHARM THERAPEUTICS INC. The 2022 Inducement Stock Incentive Plan (the “Plan”) of Karyopharm Therapeutics Inc. (the “Company”) is hereby amended as follows (all capitalized terms used and not defined herein shall have the respective meanings ascribed to such terms in the Plan): 1. Section 4(a)(1) of the Plan be and hereby

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Karyopharm Therapeutics Inc.

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 5, 2024 Karyopharm Therapeutics Inc.

Karyopharm Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress – Achieves Third Quarter 2024 Total Revenue of $38.8 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $29.5 Million; Continued Regulatory and Re

EXHIBIT 99.1 BELIEVERS IN THE EXTRAORDINARY Karyopharm Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress – Achieves Third Quarter 2024 Total Revenue of $38.8 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $29.5 Million; Continued Regulatory and Reimbursement Approvals Globally – – Following FDA Alignment, Absolute Change in Total Symptom Score (Abs-TS

Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in Myelofibrosis Co-primary Endpoint Changed to Absolute Total Symptom Score (Abs-TSS) from Total Symptom Score Improvement of ≥ 50% (TSS50) Following Align

Exhibit 99.1   Targeting Disease at the Nuclear Pore Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in Myelofibrosis Co-primary Endpoint Changed to Absolute Total Symptom Score (Abs-TSS) from Total Symptom Score Improvement of ≥ 50% (TSS50) Following Alignment with the FDA Spleen Volume Response Rate ≥ 35% (SVR35) Remains a Co-primary Endpoint Promisi

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 31, 2024 Karyopharm Therapeutics Inc.

KPTI / Karyopharm Therapeutics Inc. / HIGHBRIDGE CAPITAL MANAGEMENT LLC - KARYOPHARM THERAPEUTICS INC. Passive Investment

SC 13G 1 p24-2995sc13g.htm KARYOPHARM THERAPEUTICS INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Karyopharm Therapeutics Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 48576U106 (CUSIP Number) September 30, 2024 (Date of event which requires filing of this state

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 16, 2024 Karyopharm Therapeutics Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 26, 2024 Karyopharm Therapeu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 26, 2024 Karyopharm Therapeutics Inc.

Transition Agreement, dated as of August 29, 2024, between the Company and Michael Mason

EX-10.1 Exhibit 10.1 TRANSITION AGREEMENT This Transition Agreement (the “Agreement”) is made as of August 29, 2024 (“the Agreement Effective Date”) by and between Karyopharm Therapeutics Inc. (the “Company”) and Michael Mason (“Executive”) (together, the “Parties”). Capitalized terms used but not defined herein have the meanings set forth in the 2019 Offer Letter by and between Executive and the

Consulting Agreement, dated as of August 29, 2024, between the Company and Michael Mason

EX-10.2 Exhibit 10.2 CONSULTING AGREEMENT This Consulting Agreement (the “Agreement”), effective as of the Effective Date (as defined herein), is entered into between Karyopharm Therapeutics Inc. (the “Company”) and Michael Mason (the “Consultant”). The Consultant and the Company are referred to in this Agreement individually as a “Party” and collectively as the “Parties”. WHEREAS, the Company wis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00

Karyopharm Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress – Achieves Second Quarter 2024 Total Revenue of $42.8 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $28.0 Million; Positive Momentum ex-US w

EX-99.1 Exhibit 99.1   BELIEVERS IN THE EXTRAORDINARY Karyopharm Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress – Achieves Second Quarter 2024 Total Revenue of $42.8 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $28.0 Million; Positive Momentum ex-US with Continued Regulatory and Reimbursement Approvals – – Updated Clinical Results at ASCO Annual

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 6, 2024 Karyopharm Therapeut

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 6, 2024 Karyopharm Therapeutics Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 1) (Rule 13e-4) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 KARYOPHARM THERAPEUTICS INC. (Name of

SC TO-I/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 1) (Rule 13e-4) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 KARYOPHARM THERAPEUTICS INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Options to Purchase Common Stock, $0.0001 Par Value Per Share (Title of Class of Secur

Offer to Exchange Eligible Options for New Restricted Stock Units, dated June 20, 2024

EX-99.(a)(1)(A) Exhibit (a)(1)(A) OFFER TO EXCHANGE ELIGIBLE OPTIONS FOR NEW RESTRICTED STOCK UNITS KARYOPHARM THERAPEUTICS INC. THIS OFFER AND WITHDRAWAL RIGHTS EXPIRE AT 11:59 P.M., EASTERN TIME, ON JULY 18, 2024 UNLESS THIS OFFER IS EXTENDED Unless the context requires otherwise, references in this Offer to Exchange to “Karyopharm,” the “Company,” “we,” “us,” and “our” refer to Karyopharm Thera

Form of follow-up Email to Employees from Chief Human Resources Officer

EX-99.(a)(1)(C) Exhibit (a)(1)(C) To: Eligible Holders From: Lisa DiPaolo Subject: Launch of Karyopharm One-Time Stock Option Exchange Program All, As a follow-up to my email from April 8, 2024, I’m pleased to announce that today we are formally launching a voluntary one-time stock option exchange program for eligible employees following stockholder approval of this important compensation program

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 13e-4) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 KARYOPHARM THERAPEUTICS INC. (Name of Subject Company (I

SC TO-I UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 13e-4) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 KARYOPHARM THERAPEUTICS INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Options to Purchase Common Stock, $0.0001 Par Value Per Share (Title of Class of Securities) 48576U106 (CU

Form of Announcement Email

EX-99.(a)(1)(D) Exhibit (a)(1)(D) Dear Karyopharm Employees: IMPORTANT NEWS — PLEASE READ. IF YOU CHOOSE TO PARTICIPATE IN THE OPTION EXCHANGE, YOU MUST TAKE ACTION BY 11:59 PM EASTERN TIME ON JULY 18, 2024. We are pleased to announce that the stock option exchange program that you have previously received notice of (the “Option Exchange”) begins today. You are receiving this email because you are

Form of Reminder Email

EX-99.(a)(1)(G) Exhibit (a)(1)(G) Karyopharm Option Exchange Program According to our records, you have not yet submitted an election in connection with Karyopharm’s Option Exchange program. This email is to remind you that July 18, 2024 at 11:59 P.M. Eastern Time is the final deadline to submit an election to participate in the Option Exchange. The Option Exchange deadline will be strictly enforc

Screenshots of Option Exchange Website

EX-99.(a)(1)(H) Exhibit (a)(1)(H) MyOptionExchange WELCOME ELECTION FORM VALUE CALCULATOR RESOURCES ADMIN LOGOUT ZTZ INFINITE ZlZ EQUITY Welcome Option Exchange Program Commencement Date: June 20,2024 Expiration Time: July 18,2024 at 11:59 P.M. Eastern Time We are offering you the opportunity to exchange some or all of your eligible stock options, as described in the Offer to Exchange Eligible Opt

Terms of Election

EX-99.(a)(1)(E) Exhibit (a)(1)(E) KARYOPHARM THERAPEUTICS INC. TERMS OF ELECTION BY PARTICIPATING, YOU AGREE TO ALL TERMS OF THE OPTION EXCHANGE AS SET FORTH IN THE OFFER TO EXCHANGE ELIGIBLE OPTIONS FOR NEW RESTRICTED STOCK UNITS, DATED JUNE 20, 2024 (AS IT MAY BE AMENDED AND SUPPLEMENTED FROM TIME TO TIME, THE “OFFER TO EXCHANGE”). ALL CAPITALIZED TERMS USED AND NOT DEFINED HEREIN SHALL HAVE THE

Option Exchange Frequently Asked Questions

EX-99.(a)(1)(I) Exhibit (a)(1)(I) OPTION EXCHANGE FREQUENTLY ASKED QUESTIONS The following are answers to some of the questions that you may have about the Option Exchange. We urge you to read carefully the following questions and answers. Where applicable, we have included section references to the Offer to Exchange Eligible Options for New Restricted Stock Units, dated June 20, 2024 (the “Offer

Form of Confirmation Email

EX-99.(a)(1)(F) Exhibit (a)(1)(F) KARYOPHARM OPTION EXCHANGE PROGRAM Karyopharm has received your election via the Karyopharm Option Exchange website by which you elected to accept or reject Karyopharm’s offer to exchange eligible stock options for New RSUs with respect to some or all of your outstanding stock option grants, subject to the terms and conditions of the Offer to Exchange Eligible Opt

Employee Presentation

EX-99.(a)(1)(J) Exhibit (a)(1)(J) Option Exchange Program Informational Presentation June 20 – July 18, 2024 Disclaimer The statements in this presentation concerning the Option Exchange, Eligible Options, and the new RSUs are summaries and are not complete descriptions thereof. The Option Exchange is being made pursuant to the terms and conditions set forth in Karyopharm’s Tender Offer Statement

Filing Fee Table

EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables SCHEDULE TO (Form Type) KARYOPHARM THERAPEUTICS INC.

Communication to Employees from Chief Human Resources Officer, sent April 8, 2024

EX-99.(a)(1)(B) Exhibit (a)(1)(B) To: All Karyopharm U.S. employees From: Lisa DiPaolo Subject: Proposal for a one-time Karyopharm stock option exchange All, At Karyopharm, we are always looking for new ways to reward our people and ensure that we have competitive rewards packages to help attract, motivate, and retain our employees. I am pleased to share that our Board of Directors has approved a

June 5, 2024

June 5, 2024 VIA EDGAR SUBMISSION Securities and Exchange Commission Division of Corporation Finance, Office of Life Sciences 100 F Street, NE Washington, DC 20549 Attention: Chris Edwards Re: Karyopharm Therapeutics Inc.

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 29, 2024 Karyopharm Therapeutics Inc.

Filing Fee Table

EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Karyopharm Therapeutics Inc.

As filed with the Securities and Exchange Commission on May 30, 2024

S-3 Table of Contents As filed with the Securities and Exchange Commission on May 30, 2024 Registration No.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Karyopharm Therapeutics Inc.

As filed with the Securities and Exchange Commission on May 30, 2024

As filed with the Securities and Exchange Commission on May 30, 2024 Registration No.

KPTI / Karyopharm Therapeutics Inc. / J. WOOD CAPITAL ADVISORS LLC Passive Investment

SC 13G 1 formsc13g.htm United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Karyopharm Therapeutics Inc. (Name of Issuer) Common Stock (Title of Class of

Joint Filing Agreement.

EX-99 2 ex99.htm Exhibit 99 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that they are jointly filing this statement on Schedule 13G. Each of them is responsible for the timely filing of such statement and any amendments thereto, and for the completeness and accuracy of the information con

Second Omnibus Amendment to Transaction Documents, dated May 8, 2024, between the Company, the investors party thereto, HealthCare Royalty Management, LLC, HCR Collateral Management LLC, and HCR Karyopharm SPV, LLC.

Exhibit 10.4 SECOND OMNIBUS AMENDMENT TO TRANSACTION DOCUMENTS This SECOND OMNIBUS AMENDMENT TO TRANSACTION DOCUMENTS, dated as of May 8, 2024 (this “Second Omnibus Amendment”), is by and among KARYOPHARM THERAPEUTICS INC. (the “Company”), KARYOPHARM EUROPE GMHB (“Karyopharm Europe”), HEALTHCARE ROYALTY PARTNERS III, L.P. (“HCRP Fund III”), HEALTHCARE ROYALTY PARTNERS IV, L.P. (“HCRP Fund IV” and

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 13, 2024 Karyopharm Therapeutic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 13, 2024 Karyopharm Therapeutics Inc.

Form of Registration Rights Agreement, dated May 13, 2024, by and among the Company and the other parties thereto.

Exhibit 10.3 FORM OF REGISTRATION RIGHTS AGREEMENT among THE INITIAL INVESTORS PARTY HERETO and KARYOPHARM THERAPEUTICS INC. Dated as of May 13, 2024 REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of May 13, 2024, by and among KARYOPHARM THERAPEUTICS INC., a Delaware corporation, with its principal offices at 85 Wells Avenue, 2nd Floor, Newton, MA 02459 (t

Form of Exchange Agreement, dated May 8, 2024, by and among the Company and the other parties thereto.

Exhibit 10.2 May 8, 2024 Karyopharm Therapeutics Inc. 85 Wells Avenue, Suite 210 Newton, MA 02459 Attention: Chief Financial Officer Re: Exchange for Karyopharm Therapeutics Inc. 6.00% Convertible Senior Notes due 2029 and Warrants to Purchase Common Stock Ladies and Gentlemen: Karyopharm Therapeutics Inc., a Delaware corporation (the “Company”), is proposing to exchange its outstanding 3.00% Conv

Form of Warrant to Purchase Common Stock.

Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

Credit Agreement, dated as of May 8, 2024, between the Company, the guarantors party thereto, the lenders party thereto, and Wilmington Savings Fund Society, FSB, as administrative agent and collateral agent.

Exhibit 10.1 Execution Version CREDIT AND GUARANTY AGREEMENT dated as of May 8, 2024 among KARYOPHARM THERAPEUTICS INC. as borrower, and CERTAIN SUBSIDIARIES OF BORROWER, as Guarantors, VARIOUS LENDERS, WILMINGTON SAVINGS FUND SOCIETY, FSB, as Administrative Agent and Collateral Agent $100,000,000 Senior Secured Credit Facilities TABLE OF CONTENTS Page SECTION 1 DEFINITIONS AND INTERPRETATION 1   

Indenture (including form of Note) with respect to the Company’s 6.00% Convertible Senior Notes due 2029, dated May 13, 2024, between the Company, the guarantors party thereto and Wilmington Savings Fund Society, FSB, as trustee and collateral agent.

Exhibit 4.1 Execution Version KARYOPHARM THERAPEUTICS INC., as Issuer THE GUARANTORS PARTY HERETO, AND WILMINGTON SAVINGS FUND SOCIETY, FSB, as Trustee and Collateral Agent INDENTURE Dated as of May 13, 2024 6.00% Convertible Senior Notes due 2029 TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions 1 Section 1.02 References to Interest 31 Section 1.03 Divisions 31 Section 1.04

Karyopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast Majority of Its Debt Maturities into 2028 and 2029 – $148.0 Million (86%) of Existing Convertible Notes due in 2025 to be Exchanged for $111.0 Mill

Exhibit 99.1 Targeting Disease at the Nuclear Pore Karyopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast Majority of Its Debt Maturities into 2028 and 2029 – $148.0 Million (86%) of Existing Convertible Notes due in 2025 to be Exchanged for $111.0 Million of New Convertible Notes due in 2029 and Warrants – – Issues New $100.0 Million Senior Secured

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0

Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress – Announces Significant Refinancing Transactions and Amends Royalty Agreement with HealthCare Royalty Extending Vast Majority of Its Debt Maturities into 2

Exhibit 99.1 Targeting Disease at the Nuclear Pore Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress – Announces Significant Refinancing Transactions and Amends Royalty Agreement with HealthCare Royalty Extending Vast Majority of Its Debt Maturities into 2028 and 2029, Well Beyond Expected Data Readouts and Potential Approvals from the Company’s Three P

Offer Letter, dated as of April 4, 2022, between the Registrant and Reshma Rangwala.

Exhibit 10.2 85 Wells Ave. Newton, MA April 4, 2022 Reshma Rangwala Via Email Dear Reshma, I am pleased to offer you the position of Executive Vice President and Chief Medical Officer with Karyopharm Therapeutics Inc. (the "Company"), reporting directly to Richard Paulson. This is an important position in the Company, and I know it will be a challenging and exciting one. We anticipate your start d

Non-Employee Director Compensation Policy.

Exhibit 10.1 KARYOPHARM THERAPEUTICS INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Effective May 21, 2021 (as amended June 30, 2022, February 10, 2023 and March 14, 2024) The purpose of this Non-Employee Director Compensation Policy (this “Policy”) of Karyopharm Therapeutics Inc. (the “Company”) is to provide a total compensation package that enables the Company to attract and retain, on a long-t

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 8, 2024 Karyopharm Therapeutics Inc.

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 8, 2024 Karyopharm Therapeutics Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Karyopharm Therapeutics Inc. (Name of Subject Compan

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Karyopharm Therapeutics Inc. (Name of Subject Company (Issuer) and Filing Person (as Offeror)) Options to Purchase Common Stock, par value $0.0001 per share (Title of Class of Securities) 48576U106 (CUS

Communication to Employees from Chief Human Resources Officer, sent April 8, 2024.

Exhibit 99.2 To: All Karyopharm U.S. employees From: Lisa DiPaolo Subject: Proposal for a one-time Karyopharm stock option exchange All, At Karyopharm, we are always looking for new ways to reward our people and ensure that we have competitive rewards packages to help attract, motivate, and retain our employees. I am pleased to share that our Board of Directors has approved a voluntary one-time Ka

2

April 3, 2024 By Electronic Submission Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 29, 2024 Karyopharm Therapeutics Inc.

Subsidiaries of the Registrant

Exhibit 21.1 Subsidiaries of Karyopharm Therapeutics Inc. Jurisdiction of Incorporation or Organization Karyopharm Securities Corp. Massachusetts Karyopharm Europe GmbH Germany Karyopharm Israel Ltd. Israel

Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress – Total Revenue of $146 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $112 Million for Full Year 2023, Meeting Company’s Guida

Exhibit 99.1 Targeting Disease at the Nuclear Poreh3 Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress – Total Revenue of $146 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $112 Million for Full Year 2023, Meeting Company’s Guidance – – Top-Line Data Readouts from Three Pivotal Phase 3 Trials Evaluating Selinexor in Endometr

Dodd-Frank Compensation Recovery Policy

Exhibit 97 KARYOPHARM THERAPEUTICS INC. Dodd-Frank Compensation Recovery Policy This Compensation Recovery Policy (this “Policy”) is adopted by Karyopharm Therapeutics Inc. (the “Company”) in accordance with Nasdaq Listing Rule 5608 (“Rule 5608”), which implements Rule 10D-1 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (as promulgated pursuant to Section 954 of the Do

Karyopharm Therapeutics Inc. Annual Bonus Plan

Exhibit 10.28 KARYOPHARM THERAPEUTICS INC. ANNUAL BONUS PLAN I. Objective The Karyopharm Therapeutics Inc. (“Karyopharm” or the “Company”) Annual Bonus Plan (the “Plan”) has been established to attract, motivate, and retain employees by promoting and rewarding the achievement of key short-term corporate objectives as well as individual performance and to align the interests of employees and stockh

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-3616

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 16, 2024 Karyopharm Therap

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 16, 2024 Karyopharm Therapeutics Inc.

KPTI / Karyopharm Therapeutics Inc. / Avidity Partners Management LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

KPTI / Karyopharm Therapeutics Inc. / Palo Alto Investors LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 8)* Karyopharm Therapeutics Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 48576U106 (CUSIP Number) December 31, 2023 (Date of Event which

KPTI / Karyopharm Therapeutics Inc. / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Karyopharm Therapeutics Inc Title of Class of Securities: Common Stock CUSIP Number: 48576U106 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(

KPTI / Karyopharm Therapeutics Inc. / Rubric Capital Management LP - SC 13G/A Passive Investment

SC 13G/A 1 tm245464d11sc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Karyopharm Therapeutics Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 48576U106 (CUSIP Number) December 31, 2023 (Date of event which requires filing of this statement) Check

Karyopharm Announces Preliminary Unaudited 2023 Revenue and 2024 Objectives – Accelerating Innovation and Growth Strategy with Top-Line Data Readouts Expected in 2H 2024 and 2025 from Three Pivotal Phase 3 Studies Evaluating Selinexor in Multiple Mye

EX-99.1 Exhibit 99.1 Targeting Disease at the Nuclear Pore Karyopharm Announces Preliminary Unaudited 2023 Revenue and 2024 Objectives – Accelerating Innovation and Growth Strategy with Top-Line Data Readouts Expected in 2H 2024 and 2025 from Three Pivotal Phase 3 Studies Evaluating Selinexor in Multiple Myeloma, Endometrial Cancer and Myelofibrosis – – Preliminary Unaudited Full Year 2023 Total R

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 8, 2024 Karyopharm Therapeu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 8, 2024 Karyopharm Therapeutics Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 6, 2023 Karyopharm Therape

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 6, 2023 Karyopharm Therapeutics Inc.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 5, 2023 Karyopharm Therapeutics Inc.

Karyopharm Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress – Achieved Third Quarter 2023 Total Revenue of $36.0 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $30.2 Million – – Maintains Full Year 2023

EX-99.1 Exhibit 99.1 Targeting Disease at the Nuclear Pore Karyopharm Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress – Achieved Third Quarter 2023 Total Revenue of $36.0 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $30.2 Million – – Maintains Full Year 2023 Total Revenue Guidance of $145 Million to $160 Million, Including U.S. XPOVIO Net Product

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 2, 2023 Karyopharm Therapeutics Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 31, 2023 Karyopharm Therapeu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 31, 2023 Karyopharm Therapeutics Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00

Karyopharm Therapeutics Inc. Annual Bonus Plan.

Exhibit 10.5 KARYOPHARM THERAPEUTICS INC. ANNUAL BONUS PLAN I. Objective The Karyopharm Therapeutics Inc. (“Karyopharm” or the “Company”) Annual Bonus Plan (the “Plan”) has been established to attract, motivate, and retain employees by promoting and rewarding the achievement of key short-term corporate objectives as well as individual performance and to align the interests of employees and stockho

Filing Fee Table

EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Karyopharm Therapeutics Inc.

Common Stock Purchase Warrant, dated August 1, 2023, issued to Healthcare Royalty Partners III, L.P. (incorporated by reference to Exhibit 4.1 to the Registrant's Form 10-Q (File No. 001-36167) filed with the Commission on August 2, 2023)

Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 2, 2023 Karyopharm Therapeutics Inc.

Karyopharm Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress – Achieved Second Quarter 2023 Total Revenue of $37.6 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $28.5 Million – – Maintains Full Year 20

EX-99.1 Exhibit 99.1 Targeting Disease at the Nuclear Pore Karyopharm Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress – Achieved Second Quarter 2023 Total Revenue of $37.6 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $28.5 Million – – Maintains Full Year 2023 Total Revenue Guidance of $145 Million to $160 Million, Including U.S. XPOVIO Net Produc

As filed with the Securities and Exchange Commission on August 2, 2023

S-8 As filed with the Securities and Exchange Commission on August 2, 2023 Registration No.

Restated Certificate of Incorporation of the Registrant, as amended

Exhibit 3.1 RESTATED CERTIFICATE OF INCORPORATION OF KARYOPHARM THERAPEUTICS INC. (originally incorporated on December 22, 2008) FIRST: The name of the Corporation is Karyopharm Therapeutics Inc. (the “Corporation”). SECOND: The address of the Corporation’s registered office in the State of Delaware is Corporation Trust Center, 1209 Orange Street, in the City of Wilmington, County of New Castle, 1

Second Amendment to Revenue Interest Financing Agreement, dated as of August 1, 2023, by and among the Registrant, Karyopharm Europe GmbH, HealthCare Royalty Partners III, L.P., HealthCare Royalty Partners IV, L.P., HCRP Overflow Fund, L.P., HCR Stafford Fund, L.P., HCR Canary Fund, L.P., HCR Potomac Fund, L.P., HCR Molag Fund, L.P., HealthCare Royalty Management, LLC and HCR Collateral Management, LLC.

Exhibit 10.4 SECOND AMENDMENT TO REVENUE INTEREST FINANCING AGREEMENT This SECOND AMENDMENT TO REVENUE INTEREST FINANCING AGREEMENT, dated as of August 1, 2023 (this “Amendment”), is by and among KARYOPHARM THERAPEUTICS INC. (the “Company”), KARYOPHARM EUROPE GMBH, HEALTHCARE ROYALTY PARTNERS III, L.P. (“HCRP Fund III”), HEALTHCARE ROYALTY PARTNERS IV, L.P. (“HCRP Fund IV”), HCRP OVERFLOW FUND, L.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 24, 2023 Karyopharm Therapeutic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 24, 2023 Karyopharm Therapeutics Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 4, 2023 Karyopharm Therapeutics

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 4, 2023 Karyopharm Therapeutics Inc.

Poulton (incorporated by reference to Exhibit 10.5 to the Registrant's Current Report on Form 10-Q (File No. 001-36167) filed with the Commission on May 4, 2023)

Exhibit 10.5 August 5, 2022 Stuart Poulton Dear Stuart, Thank you for all you have done to contribute to Karyopharm’s continued success. As discussed, we are happy to promote you to Executive Vice President, Chief Development Officer, effective July 27th, 2022. We believe this position will be a challenging and exciting one. In connection with your promotion, your semi-monthly salary will be $18,7

Offer Letter, dated as of January 13, 2022, between the Registrant and Stuart Poulton.

Exhibit 10.6 85 Wells Ave. Newton, MA January 13, 2022 Stuart Poulton Via Email Dear Stuart, I am pleased to offer you the position of Senior Vice President, Strategy and Portfolio Management with Karyopharm Therapeutics Inc. (the "Company"), reporting directly to Richard Paulson. This is an important position in the Company, and I know it will be a challenging and exciting one. We anticipate your

Amendment No. 1 to License Agreement, dated May 19, 2022, by and between the Registrant and Berlin-Chemie AG.

Exhibit 10.3 AMENDMENT NO. 1 TO LICENSE AGREEMENT BY AND BETWEEN KARYOPHARM THERAPEUTICS INC. AND BERLIN-CHEMIE AG THIS AMENDMENT NO. 1 (the “Amendment”) is made and entered into as of May 19, 2022 (the “Amendment Effective Date”), by and between Karyopharm Therapeutics Inc., a corporation organized and existing under the law of Delaware and having its principal place of business at 85 Wells Ave.,

Amendment No. 2 to License Agreement, dated March 14, 2023, by and between the Registrant and Berlin-Chemie AG.

Exhibit 10.4 AMENDMENT NO. 2 TO LICENSE AGREEMENT BY AND BETWEEN KARYOPHARM THERAPEUTICS INC. AND BERLIN-CHEMIE AG THIS AMENDMENT NO. 2 (the “Amendment”) is made and entered into as of March 14, 2023 (the “Amendment Effective Date”), by and between Karyopharm Therapeutics Inc., a corporation organized and existing under the law of Delaware and having its principal place of business at 85 Wells Ave

Promotion Letter, dated as of December 31, 2021, between the Registrant and Sohanya Cheng.

Exhibit 10.7 December 31, 2021, Dear Sohanya, Thank you for all you have done to contribute to Karyopharm’s continued success. As discussed, we are happy to promote you to Executive Vice President, Chief Commercial Officer, effective December 16, 2021. We believe this position will be a challenging and exciting one. In connection with your promotion, your semi-monthly salary will increase to $18,7

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0

Karyopharm Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress – Achieved First Quarter 2023 Total Revenues of $38.7 Million, including XPOVIO® (selinexor) Net Product Revenue of $28.3 Million, Adversely Impacted by In

EX-99.1 Exhibit 99.1 Targeting Disease at the Nuclear Pore Karyopharm Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress – Achieved First Quarter 2023 Total Revenues of $38.7 Million, including XPOVIO® (selinexor) Net Product Revenue of $28.3 Million, Adversely Impacted by Increased Utilization of Patient Assistant Programs (PAP) and Higher Gross to Net; YoY Growth

Offer Letter, dated as of June 1, 2021, between the Registrant and Sohanya Cheng.

Exhibit 10.8 85 Wells Ave. Newton, MA June 1, 2021 Sohanya Cheng Via email Dear Sohanya, I am pleased to offer you the position of SVP, Sales and Commercial Operations with Karyopharm Therapeutics Inc. (the "Company"), reporting directly to Richard Paulson, CEO and President. This is an important position in the Company, and I know it will be a challenging and exciting one. We anticipate your star

Offer Letter, dated as of November 24, 2020, between the Registrant and Michael Mano.

Exhibit 10.9 85 Wells Ave. Newton, MA November 24, 2020 Michael Mano Via Email Dear Michael, I am pleased to offer you the position of Senior Vice President, and General Counsel with Karyopharm Therapeutics Inc. (the "Company"), reporting directly to The Office of the CEO & President. This is an important position in the Company and I know it will be a challenging and exciting one. We anticipate y

May 3, 2023

CORRESP May 3, 2023 VIA EDGAR SUBMISSION Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Attention: Arzhang Navai Re: Karyopharm Therapeutics Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

Amended and Restated 2013 Employee Stock Purchase Plan

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 10, 2023 Karyopharm Therapeut

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 10, 2023 Karyopharm Therapeutics Inc.

Amendment No. 2 to the 2022 Inducement Stock Incentive Plan

EX-99.4 Exhibit 99.4 AMENDMENT NO. 2 TO 2022 INDUCEMENT STOCK INCENTIVE PLAN OF KARYOPHARM THERAPEUTICS INC. The 2022 Inducement Stock Incentive Plan (the “Plan”) of Karyopharm Therapeutics Inc. (the “Company”) is hereby amended as follows (all capitalized terms used and not defined herein shall have the respective meanings ascribed to such terms in the Plan): 1. Section 4(a)(1) of the Plan be and

Form of Subordinated Indenture

EX-4.2 Exhibit 4.2 KARYOPHARM THERAPEUTICS INC. and Trustee INDENTURE Dated as of SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE 1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a

Non-Employee Director Compensation Policy

Exhibit 10.29 KARYOPHARM THERAPEUTICS INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Effective May 21, 2021 (as amended June 30, 2022 and February 10, 2023) The purpose of this Non-Employee Director Compensation Policy (this “Policy”) of Karyopharm Therapeutics Inc. (the “Company”) is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-3616

2022 Israeli Equity Incentive Sub Plan to the 2022 Equity Incentive Plan

Exhibit 10.25 KARYOPHARM THERAPEUTICS INC. 2022 ISRAELI EQUITY INCENTIVE SUB PLAN TO THE 2022 EQUITY INCENTIVE PLAN 1. General. 1.1. This 2022 Israeli Equity Incentive Sub Plan (the “Sub Plan”) is a sub plan to the 2022 Equity Incentive Plan (the “Plan”) of Karyopharm Therapeutics Inc. (the “Company”) and sets forth the terms for the grant of Awards (as defined in the Plan) to Israeli Employees or

As filed with the Securities and Exchange Commission on February 17, 2023

S-8 As filed with the Securities and Exchange Commission on February 17, 2023 Registration No.

Form of Senior Note

EX-4.3 Exhibit 4.3 Form of Senior Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE

Form of Subordinated Note

EX-4.4 Exhibit 4.4 Form of Subordinated Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER N

Form of Senior Indenture

EX-4.1 Exhibit 4.1 KARYOPHARM THERAPEUTICS INC. and Trustee INDENTURE Dated as of SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02

Filing Fee Table

EX-FILING FEES 9 d721068dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Karyopharm Therapeutics Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximu

Form of Restricted Stock Unit Agreement (Time Vested) under the 2022 Equity Incentive Plan adopted February 9, 2023 (incorporated by reference to Exhibit 10.14 to the Registrant's Annual Report on Form 10-K (File No. 001-36167) filed with the Commission on February 17, 2023)

Exhibit 10.14 KARYOPHARM THERAPEUTICS INC. Restricted Stock Unit Agreement (Time Vested) 2022 Equity Incentive Plan NOTICE OF GRANT This Restricted Stock Unit Agreement (this “Agreement”) is made as of the Agreement Date between Karyopharm Therapeutics Inc. (the “Company”), a Delaware corporation, and the Participant. Agreement Date and Number Agreement Date: Agreement Number: (a) Participant Info

Form of Restricted Stock Unit Agreement (Time Vested) under the 2022 Inducement Stock Incentive Plan adopted February 9, 2023 (incorporated by reference to Exhibit 10.23 to the Registrant's Annual Report on Form 10-K (File No. 001-36167) filed with the Commission on February 17, 2023)

Exhibit 10.23 KARYOPHARM THERAPEUTICS INC. Restricted Stock Unit Agreement 2022 Inducement Stock Incentive Plan NOTICE OF GRANT This Restricted Stock Unit Agreement (this “Agreement”) is made as of the Agreement Date between Karyopharm Therapeutics Inc. (the “Company”), a Delaware corporation, and the Participant pursuant to the Company’s 2022 Inducement Stock Incentive Plan (the “Plan”). I. Agree

As filed with the Securities and Exchange Commission on February 17, 2023

S-3 Table of Contents As filed with the Securities and Exchange Commission on February 17, 2023 Registration No.

Subsidiaries of the Registrant

Exhibit 21.1 Subsidiaries of Karyopharm Therapeutics Inc. Jurisdiction of Incorporation or Organization Karyopharm Securities Corp. Massachusetts Karyopharm Europe GmbH Germany Karyopharm Israel Ltd. Israel

Filing Fee Table

EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Karyopharm Therapeutics Inc.

Amendment No. 2 to the 2022 Inducement Stock Incentive Plan

Exhibit 10.20 AMENDMENT NO. 2 TO 2022 INDUCEMENT STOCK INCENTIVE PLAN OF KARYOPHARM THERAPEUTICS INC. The 2022 Inducement Stock Incentive Plan (the “Plan”) of Karyopharm Therapeutics Inc. (the “Company”) is hereby amended as follows (all capitalized terms used and not defined herein shall have the respective meanings ascribed to such terms in the Plan): 1. Section 4(a)(1) of the Plan be and hereby

Open Market Sale AgreementSM, dated as of February 17, 2023, by and between the Registrant and Jefferies LLC (incorporated by reference to Exhibit 1.2 to the Registrant’s Registration Statement on Form S-3 (File No. 333-269846) filed with the Commission on February 17, 2023)

EX-1.2 2 d721068dex12.htm EX-1.2 Exhibit 1.2 OPEN MARKET SALE AGREEMENTSM February 17, 2023 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Karyopharm Therapeutics Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 9, 2023 Karyopharm Therape

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 9, 2023 Karyopharm Therapeutics Inc.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 15, 2023 Karyopharm Therapeutics Inc.

Karyopharm Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress — Total Revenue of $157.1 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $120.4 Million for Full Year 2022, Meeting Company’s G

EX-99.1 Exhibit 99.1 Targeting Disease at the Nuclear Pore Karyopharm Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress — Total Revenue of $157.1 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $120.4 Million for Full Year 2022, Meeting Company’s Guidance — — Updated Results from the Phase 1 Study of Selinexor in Combination with Ruxolit

Form of Restricted Stock Unit Agreement (Performance Vested) under the 2022 Equity Incentive Plan adopted February 9, 2023 (incorporated by reference to Exhibit 10.1 to the Registrant's Current Report on Form 8-K (File No. 001-36167) filed with the Commission on February 15, 2023)

EX-10.1 Exhibit 10.1 KARYOPHARM THERAPEUTICS INC. Restricted Stock Unit Agreement (Performance Vested) 2022 Equity Incentive Plan NOTICE OF GRANT This Restricted Stock Unit Agreement (this “Agreement”) is made as of the Agreement Date between Karyopharm Therapeutics Inc. (the “Company”), a Delaware corporation, and the Participant. Agreement Date: Agreement Number: I. Participant Information Parti

Power of Attorney, dated February 13, 2023, made by Anastasis Nikolaou and Chione Limited in favor of Shalom Leaf*

Exhibit 24.4 LIMITED POWER OF ATTORNEY The undersigned, Anastasis Nikolaou, hereby appoints Shalom Leaf as his attorney-in-fact (i) for and on behalf of the undersigned, including, without limitation, in my current or future capacity as a director and, if applicable, as an officer of Chione Limited (the “Company”), and (ii) for and on behalf of the Company, in each case, in respect of (A) any curr

KPTI / Karyopharm Therapeutics Inc / COMMODORE CAPITAL LP Passive Investment

SC 13G/A 1 formsc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Karyopharm Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 48576U106 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the a

Power of Attorney, dated as of February 13, 2023, made by Marcin Czernik and Chione Limited in favor of Shalom Leaf*

Exhibit 24.1 LIMITED POWER OF ATTORNEY The undersigned, Marcin Czernik, hereby appoints Shalom Leaf as his attorney-in-fact (i) for and on behalf of the undersigned, including, without limitation, in my current or future capacity as a director and, if applicable, as an officer of Chione Limited (the “Company”), and (ii) for and on behalf of the Company, in each case, in respect of (A) any current

Power of Attorney, dated February 13, 2023, made by Wiaczeslaw Smolokowski in favor of Shalom Leaf*

Exhibit 24.3 LIMITED POWER OF ATTORNEY The undersigned, Wiaczeslaw Smolokowski, hereby appoints Shalom Leaf as his attorney-in-fact for and on behalf of the undersigned, in respect of (A) any current or future direct or indirect beneficial ownership of, or pecuniary interest in (whether or not such beneficial ownership or pecuniary interest is disclaimed), securities of Karyopharm Therapeutics Inc

KPTI / Karyopharm Therapeutics Inc / Avidity Partners Management LP Passive Investment

SC 13G/A 1 d988173213g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Karyopharm Therapeutics Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 48576U106 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropria

JOINT FILING AGREEMENT

Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that Amendment No. 8 to the Schedule 13G, dated as of February 14, 2023, with respect to the Common Stock of Karyopharm Therapeutics Inc. is, and any amendments thereto, any Schedule 13D with respect to such Common Stock, and any amendments thereto, signed by each of the undersigned shall be, filed on behalf of each of us pursuant to

Power of Attorney, dated as of February 13, 2023, made by Andreas Hadjimichael and Chione Limited in favor of Shalom Leaf*

EX-24.2 3 ea173459ex24-2karyo.htm POWER OF ATTORNEY, DATED AS OF FEBRUARY 13, 2023, MADE BY ANDREAS HADJIMICHAEL AND CHIONE LIMITED IN FAVOR OF SHALOM LEAF Exhibit 24.2 LIMITED POWER OF ATTORNEY The undersigned, Andreas Hadjimichael, hereby appoints Shalom Leaf as his attorney-in-fact (i) for and on behalf of the undersigned, including, without limitation, in my current or future capacity as a dir

KPTI / Karyopharm Therapeutics Inc / Chione Ltd - AMENDMENT NO. 8 TO SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 8)* Karyopharm Therapeutics Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 48576U106 (CUSIP Number) Simon Prisk, Esq. 150 East 58th Street, 22nd Floor New York, NY 10155 (212) 355-3333 (Name, Address and Telephone Number of Person Authoriz

KPTI / Karyopharm Therapeutics Inc / Rubric Capital Management LP - SC 13G Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Karyopharm Therapeutics Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 48576U106 (CUSIP Number) December 31, 2022 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pur

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 9, 2023 Karyopharm Therapeu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 9, 2023 Karyopharm Therapeutics Inc.

Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Revenue and Outlines 2023 Objectives – Preliminary Unaudited Full Year 2022 Total Revenue and U.S. XPOVIO® (selinexor) Net Product Revenue Expected to be Approximately $157.

EX-99.1 2 d435746dex991.htm EX-99.1 Exhibit 99.1 Targeting Disease at the Nuclear Pore Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Revenue and Outlines 2023 Objectives – Preliminary Unaudited Full Year 2022 Total Revenue and U.S. XPOVIO® (selinexor) Net Product Revenue Expected to be Approximately $157.7 Million and $120.4 Million, Respectively, Meeting Company’s G

December 29, 2022

CORRESP 1 filename1.htm December 29, 2022 VIA EDGAR SUBMISSION Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Attention: Tim Buchmiller Re: Karyopharm Therapeutics Inc. Registration Statement on Form S-3 File No. 333-268991 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Kary

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Karyopharm Therapeutics Inc.

As filed with the Securities and Exchange Commission on December 23, 2022

S-3 As filed with the Securities and Exchange Commission on December 23, 2022 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 10, 2022 Karyopharm Therap

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 10, 2022 Karyopharm Therapeutics Inc.

KPTI / Karyopharm Therapeutics Inc / Avidity Partners Management LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 5, 2022 Karyopharm Therapeutics Inc.

Securities Purchase Agreement, dated December 5, 2022 by and among the Registrant and the other parties thereto (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K (File No. 001-36167) filed with the Commission on December 5, 2022)

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this ?Agreement?) is made and entered into as of December 5, 2022 by and among Karyopharm Therapeutics Inc., a Delaware corporation (the ?Company?), and the Investors identified on Exhibit A attached hereto (each an ?Investor? and collectively the ?Investors?). RECITALS A. The Company and the Investors are executing and

Registration Rights Agreement, dated December 5, 2022 by and among the Registrant and the other parties thereto (incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K (File No. 001-36167) filed with the Commission on December 5, 2022)

Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this ?Agreement?) is made and entered into as of December 5, 2022 by and among Karyopharm Therapeutics Inc., a Delaware corporation (the ?Company?), and the ?Investors? named in that certain Securities Purchase Agreement by and among the Company and the Investors, dated as of December 5, 2022 (the ?Purchase Agreement?).

Form of Warrant to Purchase Common Stock to be issued pursuant to the Securities Purchase Agreement (incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K (File No. 001-36167) filed with the Commission on December 5, 2022)

Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

Karyopharm Announces $165 Million Private Placement

Exhibit 99.1 Targeting Disease at the Nuclear Pore Karyopharm Announces $165 Million Private Placement NEWTON, Mass. ? December 5, 2022 ? Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it has entered into a securities purchase agreement with certain institutional investors for a private placement that i

Third Amended and Restated By-Laws of the Registrant

EX-3.1 Exhibit 3.1 THIRD AMENDED AND RESTATED BY-LAWS OF KARYOPHARM THERAPEUTICS INC. TABLE OF CONTENTS Page ARTICLE I STOCKHOLDERS 1 1.1 Place of Meetings 1 1.2 Annual Meeting 1 1.3 Special Meetings 1 1.4 Notice of Meetings 1 1.5 Voting List 2 1.6 Quorum 2 1.7 Adjournments 3 1.8 Voting and Proxies 3 1.9 Action at Meeting 4 1.10 Nomination of Directors 4 1.11 Notice of Business at Annual Meetings

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 2, 2022 Karyopharm Therape

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 2, 2022 Karyopharm Therapeutics Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 3, 2022 Karyopharm Therape

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 3, 2022 Karyopharm Therapeutics Inc.

Karyopharm Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress – Achieved Third Quarter 2022 Total Revenue of $36.1 Million, Including XPOVIO® (selinexor) Net Product Revenue of $32.0 Million, a 20 % Increase Over Thir

EX-99.1 Exhibit 99.1 Targeting Disease at the Nuclear Pore Karyopharm Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress – Achieved Third Quarter 2022 Total Revenue of $36.1 Million, Including XPOVIO® (selinexor) Net Product Revenue of $32.0 Million, a 20 % Increase Over Third Quarter 2021– – Initiated Phase 3 Study Evaluating Selinexor as a Maintenance Therapy in

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe

Severance Agreement, dated August 2, 2022, between the Registrant and Ran Frenkel (incorporated by reference to Exhibit 10.8 to the Registrant's Quarterly Report on Form 10-Q (File No. 001-36167) filed with the Commission on August 4, 2022)

Exhibit 10.8 VIA E-MAIL August 1, 2022 Ran Frenkel Dear Ran: As we discussed, your employment with Karyopharm Therapeutics Inc. (the ?Company?) will end effective at the close of business on August 15, 2022 (the ?Separation Date?). As we also discussed, you will be eligible to receive the severance benefits described in paragraph 1 below if you sign and return this letter agreement to me by August

Form of Stock Option Agreement under the 2022 Equity Incentive Plan (incorporated by reference to Exhibit 10.2 to the Registrant's Quarterly Report on Form 10-Q (File No. 001-36167) filed with the Commission on August 4, 2022)

Exhibit 10.2 KARYOPHARM THERAPEUTICS INC. STOCK OPTION AGREEMENT Karyopharm Therapeutics Inc. (the ?Company?) hereby grants the following stock option pursuant to its 2022 Equity Incentive Plan. The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of optionee (the ?Participant?): Grant Date: Incentive Stock Option or Nonstatutory Stock Option: Number of shares of t

Form of Restricted Stock Unit Agreement under the 2022 Israel Equity Incentive Sub Plan to the 2022 Equity Incentive Plan.

Exhibit 10.5 KARYOPHARM THERAPEUTICS INC. 2022 Israeli Equity Incentive Sub Plan to the 2022 Equity Incentive Plan Restricted Stock Unit Agreement (Time Vested) NOTICE OF GRANT This Restricted Stock Unit Agreement (this ?Agreement?) is made as of the Agreement Date between Karyopharm Therapeutics Inc. (the ?Company?), a Delaware corporation, and the Participant. Agreement Date: Agreement Number: (

Form of Restricted Stock Unit Agreement under the 2022 Equity Incentive Plan (incorporated by reference to Exhibit 10.3 to the Registrant's Quarterly Report on Form 10-Q (File No. 001-36167) filed with the Commission on August 4, 2022)

Exhibit 10.3 KARYOPHARM THERAPEUTICS INC. Restricted Stock Unit Agreement (Time Vested) 2022 Equity Incentive Plan NOTICE OF GRANT This Restricted Stock Unit Agreement (this ?Agreement?) is made as of the Agreement Date between Karyopharm Therapeutics Inc. (the ?Company?), a Delaware corporation, and the Participant. Agreement Date and Number Agreement Date: Agreement Number: (a) Participant Infor

Non-Employee Director Compensation Policy dated June 30, 2022.

Exhibit 10.7 KARYOPHARM THERAPEUTICS INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Effective May 21, 2021 (as amended June 30, 2022) The purpose of this Non-Employee Director Compensation Policy (this ?Policy?) of Karyopharm Therapeutics Inc. (the ?Company?) is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors and

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00

Consulting Agreement, dated August 2, 2022, between the Registrant and Ran Frenkel (incorporated by reference to Exhibit 10.9 to the Registrant's Quarterly Report on Form 10-Q (File No. 001-36167) filed with the Commission on August 4, 2022)

Exhibit 10.9 CONSULTING AGREEMENT This Consulting Agreement (the ?Agreement?), effective as of the Effective Date (as defined herein), is entered into between Karyopharm Therapeutics Inc. (the ?Company?) and Ran Frenkel (the ?Consultant?). The Consultant and the Company are referred to in this Agreement individually as a ?Party? and collectively as the ?Parties?. WHEREAS, the Company wishes to eng

Form of Incentive Stock Option Agreement under the 2022 Israeli Equity Incentive Sub Plan to the 2022 Equity Incentive Plan.

Exhibit 10.4 KARYOPHARM THERAPEUTICS INC. 2022 Israeli Equity Incentive Sub Plan to the 2022 Equity Incentive Plan Option Agreement NOTICE OF GRANT Karyopharm Therapeutics Inc. (the ?Company?) hereby grants the following stock option pursuant to the 2022 Israeli Equity Incentive Sub Plan to the 2022 Equity Incentive Plan. Name of optionee (the ?Participant?): Grant Date: Number of shares of the Co

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 4, 2022 Karyopharm Therapeutics Inc.

Karyopharm Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress – Achieved Second Quarter 2022 Total Revenue of $39.7 Million, Up 76% Versus Second Quarter 2021; XPOVIO® (selinexor) Net Product Revenue of $29.0 Million

Exhibit 99.1 Targeting Disease at the Nuclear Pore Karyopharm Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress ? Achieved Second Quarter 2022 Total Revenue of $39.7 Million, Up 76% Versus Second Quarter 2021; XPOVIO? (selinexor) Net Product Revenue of $29.0 Million, a 44% Increase Over Q2 2021 ? ? Received Full Marketing Authorization from the European Commissio

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 26, 2022 Karyopharm Therapeutics Inc.

Termination of a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 7, 2022 Karyopharm Therapeutics Inc.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Karyopharm Therapeutics Inc.

Amendment No. 1 to the 2022 Inducement Stock Incentive Plan

Exhibit 99.3 AMENDMENT NO. 1 TO 2022 INDUCEMENT STOCK INCENTIVE PLAN OF KARYOPHARM THERAPEUTICS INC. The 2022 Inducement Stock Incentive Plan (the ?Plan?) of Karyopharm Therapeutics Inc. (the ?Company?) is hereby amended as follows (all capitalized terms used and not defined herein shall have the respective meanings ascribed to such terms in the Plan): 1. Section 4(a)(1) of the Plan be and hereby

As filed with the Securities and Exchange Commission on June 3, 2022

As filed with the Securities and Exchange Commission on June 3, 2022 Registration No.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 19, 2022 Karyopharm Therapeutics Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confide

Joint Filing Agreement dated as of May 9, 2022, by and between Commodore Capital LP and Commodore Capital Master LP (incorporated by reference to Exhibit 1 to the Schedule 13G filed with the Securities and Exchange Commission on May 9, 2022).

Exhibit 1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned, and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements.

KPTI / Karyopharm Therapeutics Inc / COMMODORE CAPITAL LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 5, 2022 Karyopharm Therapeutics Inc.

Amendment #1 to Consulting Agreement, dated March 21, 2022, between the Registrant and Jatin Shah.

Exhibit 10.5 AMENDMENT #1 TO CONSULTING AGREEMENT BETWEEN KARYOPHARM THERAPEUTICS INC. AND JATIN SHAH, M.D. THIS AMENDMENT #1 (?Amendment?) amends the Consulting Agreement between Karyopharm Therapeutics Inc. (?Karyopharm?) and Jatin Shah, M.D. (?Consultant?) with an Effective Date of the 1st day of March 2022, (the ?Agreement?). This Amendment shall be effective as of March 21, 2022 (the ?Amendme

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0

Consulting Agreement, dated March 1, 2022, between the Registrant and Jatin Shah.

Exhibit 10.4 CONSULTING AGREEMENT This Consulting Agreement (the ?Agreement?), effective as of the Effective Date (as defined herein), is entered into between Karyopharm Therapeutics Inc. (the ?Company?) and Jatin Shah, M.D. (the ?Consultant?). The Consultant and the Company are referred to in this Agreement individually as a ?Party? and collectively as the ?Parties?. WHEREAS, the Company wishes t

Severance Agreement, dated February 18, 2022, between the Registrant and Jatin Shah.

Exhibit 10.3 VIA E-MAIL February 18, 2022 Jatin Shah, M.D. 4402 Dorothy Street Bellaire, Texas 77401 Dear Jatin: As we discussed, your employment with Karyopharm Therapeutics Inc. (the ?Company?) will end effective at the close of business on February 18, 2022 (the ?Separation Date?). As we also discussed, you will be eligible to receive the severance benefits described in paragraph 1 below if you

Karyopharm Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress – Achieved First Quarter 2022 Net Revenues of $47.7 Million, Up 105% Versus First Quarter 2021, Including $19.4 Million License Revenues from Partners – –

Exhibit 99.1 Targeting Disease at the Nuclear Pore Karyopharm Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress ? Achieved First Quarter 2022 Net Revenues of $47.7 Million, Up 105% Versus First Quarter 2021, Including $19.4 Million License Revenues from Partners ? ? XPOVIO? (selinexor) Net Product Revenue of $28.3 Million, with a 30% Increase Over Q1 2021 ? ? Prel

Side Letter to Offer Letter, dated October 1, 2020, between the Registrant and Ran Frenkel.

Exhibit 10.8 October 1, 2020 Ran Frankel Dear Ran: You and Karyopharm Therapeutics Inc. (the ?Company?) are parties to a letter agreement dated June 7, 2015, as amended on October 4, 2016, related to your employment as the Chief Development Operations Officer of the Company (the ?Letter Agreement?). This letter is to inform you that, effective August 28, 2020 the Compensation Committee of the Boar

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confide

2022 Equity Incentive Plan

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 28, 2022 Karyopharm Therapeutics Inc.

Transition Agreement, dated March 28, 2022, between the Company and Michael G. Kauffman

Exhibit 10.1 VIA ELECTRONIC MAIL March 24, 2022 Michael Kauffman, M.D., Ph.D. Dear Michael: This letter agreement confirms our agreement with respect to your planned separation from employment with Karyopharm Therapeutics Inc. (the ?Company?). As we have discussed, the Company will continue to employ you through a Transition Period (as defined below), pursuant to the terms and conditions set forth

Transition Agreement, dated March 28, 2022, between the Registrant and Sharon Shacham (incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K (File No. 001-36167) filed with the Commission on March 29, 2022)

Exhibit 10.2 EXECUTION COPY VIA ELECTRONIC MAIL March 24, 2022 Sharon Shacham, Ph.D., M.B.A. Dear Sharon: This letter agreement confirms our agreement with respect to your planned separation from employment with Karyopharm Therapeutics Inc. (the ?Company?). As we have discussed, the Company will continue to employ you through a Transition Period (as defined below), pursuant to the terms and condit

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 22, 2022 Karyopharm Therapeutics Inc.

Form of Stock Option Agreement under 2022 Inducement Stock Incentive Plan (incorporated by reference to Exhibit 10.18 to the Registrant’s Annual Report on Form 10-K (File No. 001-36167) filed with the Commission on March 1, 2022)

Exhibit 10.18 KARYOPHARM THERAPEUTICS INC. Nonstatutory STOCK OPTION AGREEMENT Granted Under 2022 Inducement Stock Incentive Plan Karyopharm Therapeutics Inc. (the ?Company?) hereby grants the following stock option to the Participant listed below pursuant to the Company?s 2022 Inducement Stock Incentive Plan (the ?Plan?). The terms and conditions attached hereto are also a part hereof. Notice of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-3616

License Agreement, dated as of December 17, 2021, between the Registrant and Berlin-Chemie AG (Menarini Group) (incorporated by reference to Exhibit 10.41 to the Registrant's Annual Report on Form 10-K (file No. 001-36167) filed with the Commission on March 1, 2022)

Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential.

Form of Restricted Stock Unit Agreement under 2013 Stock Incentive Plan adopted January 24, 2022 (incorporated by reference to Exhibit 10.11 to the Registrant's Annual Report on Form 10-K (File No. 001-36167) filed with the Commission on March 1, 2022)

Exhibit 10.11 KARYOPHARM THERAPEUTICS INC. Restricted Stock Unit Agreement (Time Vested) 2013 Stock Incentive Plan NOTICE OF GRANT This Restricted Stock Unit Agreement (this ?Agreement?) is made as of the Agreement Date between Karyopharm Therapeutics Inc. (the ?Company?), a Delaware corporation, and the Participant. I. Agreement Date and Number Agreement Date: Agreement Number: II. Participant In

Subsidiaries of the Registrant

Exhibit 21.1 Subsidiaries of Karyopharm Therapeutics Inc. Jurisdiction of Incorporation or Organization Karyopharm Securities Corp. Massachusetts Karyopharm Europe GmbH Germany Karyopharm Israel Ltd. Israel

2022 Inducement Stock Incentive Plan

Exhibit 10.17 KARYOPHARM THERAPEUTICS INC. 2022 INDUCEMENT STOCK INCENTIVE PLAN 1. Purpose The purpose of this 2022 Inducement Stock Incentive Plan (the ?Plan?) of Karyopharm Therapeutics Inc., a Delaware corporation (the ?Company?), is to advance the interests of the Company?s stockholders by enhancing the Company?s ability to attract, retain and motivate persons who are expected to make importan

Form of Restricted Stock Unit Agreement under 2022 Inducement Stock Incentive Plan (incorporated by reference to Exhibit 10.19 to the Registrant’s Annual Report on Form 10-K (File No. 001-36167) filed with the Commission on March 1, 2022)

Exhibit 10.19 KARYOPHARM THERAPEUTICS INC. Restricted Stock Unit Agreement 2022 Inducement Stock Incentive Plan NOTICE OF GRANT This Restricted Stock Unit Agreement (this ?Agreement?) is made as of the Agreement Date between Karyopharm Therapeutics Inc. (the ?Company?), a Delaware corporation, and the Participant pursuant to the Company?s 2022 Inducement Stock Incentive Plan (the ?Plan?). I. Agree

As filed with the Securities and Exchange Commission on February 28, 2022

As filed with the Securities and Exchange Commission on February 28, 2022 Registration No.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Karyopharm Therapeutics Inc.

2022 Inducement Stock Incentive Plan

Exhibit 99.3 KARYOPHARM THERAPEUTICS INC. 2022 INDUCEMENT STOCK INCENTIVE PLAN 1. Purpose The purpose of this 2022 Inducement Stock Incentive Plan (the ?Plan?) of Karyopharm Therapeutics Inc., a Delaware corporation (the ?Company?), is to advance the interests of the Company?s stockholders by enhancing the Company?s ability to attract, retain and motivate persons who are expected to make important

Joint Filing Agreement, dated February 11, 2021, among the Reporting Persons

EX-99.1 2 ea155416ex99-1karyo.htm JOINT FILING AGREEMENT, DATED FEBRUARY 11, 2021, AMONG THE REPORTING PERSONS EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that Amendment No. 7 to the Schedule 13G, dated as of February 11, 2022, with respect to the Common Stock of Karyopharm Therapeutics Inc. is, and any amendments thereto, any Schedule 13D with respect to such Common Stock, an

KPTI / Karyopharm Therapeutics Inc / Chione Ltd - AMENDMENT NO. 7 TO SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 7)* Karyopharm Therapeutics Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 48576U106 (CUSIP Number) Simon Prisk, Esq. 150 East 58th Street, 22nd Floor New York, NY 10155 (212) 355-3333 (Name, Address and Telephone Number of Person Authoriz

KPTI / Karyopharm Therapeutics Inc / Kauffman Michael - SC 13G/A Passive Investment

SC 13G/A 1 d283324dsc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 8)* KARYOPHARM THERAPEUTICS INC. (Name of Issuer) Common Stock par value $0.00

Karyopharm Announces Phase 3 SIENDO Study Meets Primary Endpoint with Statistically Significant Increase in Progression-Free Survival in Patients with Advanced or Recurrent Endometrial Cancer – Selinexor Demonstrates Statistically Significant 50% Imp

EX-99.2 3 d311593dex992.htm EX-99.2 Exhibit 99.2 Targeting Disease at the Nuclear Pore Karyopharm Announces Phase 3 SIENDO Study Meets Primary Endpoint with Statistically Significant Increase in Progression-Free Survival in Patients with Advanced or Recurrent Endometrial Cancer – Selinexor Demonstrates Statistically Significant 50% Improvement in Median Progression-Free Survival Compared to Placeb

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 8, 2022 Karyopharm Therapeutics Inc.

Karyopharm Reports Strong Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Company Progress — XPOVIO® Achieves Net Product Revenue of $98.4 Million for Full Year 2021; Company Provides Full Year 2022 XPOVIO Net Product Revenu

EX-99.1 2 d311593dex991.htm EX-99.1 Exhibit 99.1 Targeting Disease at the Nuclear Pore Karyopharm Reports Strong Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Company Progress — XPOVIO® Achieves Net Product Revenue of $98.4 Million for Full Year 2021; Company Provides Full Year 2022 XPOVIO Net Product Revenue Guidance of $135 to $145 Million - —Total Revenue of $209.8 M

Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2021 Net Product Revenues and Outlines 2022 Objectives – Unaudited Net Product Revenues of Approximately $29.7 Million for Fourth Quarter 2021 and Approximately $98.3 Million for

Exhibit 99.1 Targeting Disease at the Nuclear Pore Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2021 Net Product Revenues and Outlines 2022 Objectives ? Unaudited Net Product Revenues of Approximately $29.7 Million for Fourth Quarter 2021 and Approximately $98.3 Million for the Full Year 2021? ? Company on Track to Announce Top-Line Phase 3 Data from SIENDO Study Evaluat

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 10, 2022 Karyopharm Therapeutics Inc.

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 17, 2021 Karyopharm Therapeutics Inc.

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 8, 2021 Karyopharm Therapeutics Inc.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 2, 2021 Karyopharm Therapeutics Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe

Amendment to Asset Purchase Agreement, dated as of July 17, 2019, by and between the Registrant and Biogen MA Inc.

Exhibit 10.1 AMENDMENT TO ASSET PURCHASE AGREEMENT by and between BIOGEN MA INC. and KARYOPHARM THERAPEUTICS INC. WHEREAS, the parties desire to amend the Asset Purchase Agreement dated January 24, 2018 between Biogen MA Inc. and Karyopharm Therapeutics Inc. (the "Agreement") to address rights as to potential new inventions that may arise out of the manufacturing process in connection with the par

Karyopharm Reports Strong Third Quarter 2021 Financial Results and Provides Business — Third Quarter 2021 XPOVIO® (selinexor) Net Product Revenues of $26.7 Million, Up 32% Sequential Quarter-Over-Quarter and 25% Year-Over-Year — — Milestone-Driven Q4

Exhibit 99.1 Targeting Disease at the Nuclear Pore Karyopharm Reports Strong Third Quarter 2021 Financial Results and Provides Business Highlights ? Third Quarter 2021 XPOVIO? (selinexor) Net Product Revenues of $26.7 Million, Up 32% Sequential Quarter-Over-Quarter and 25% Year-Over-Year ? ? Milestone-Driven Q4 with Top-Line Data From Phase 3 SIENDO Study in Endometrial Cancer and Continued Initia

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 3, 2021 Karyopharm Therapeutics Inc.

Karyopharm Reports Business Highlights and Second Quarter 2021 Financial Results — Achieved Second Quarter 2021 XPOVIO® (selinexor) Net Product Revenues of $20.2 Million and $41.9 Million YTD, Up 8% Versus Second Quarter 2020 and Up 21% Versus First

Exhibit 99.1 Targeting Disease at the Nuclear Pore Karyopharm Reports Business Highlights and Second Quarter 2021 Financial Results ? Achieved Second Quarter 2021 XPOVIO? (selinexor) Net Product Revenues of $20.2 Million and $41.9 Million YTD, Up 8% Versus Second Quarter 2020 and Up 21% Versus First Half of 2020 ? ? Looking Forward to a Milestone-Driven Second Half of 2021, Including Top-Line Data

Non-Employee Director Compensation Policy, dated as of May 12, 2021.

Exhibit 10.2 KARYOPHARM THERAPEUTICS INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Effective May 21, 2021 The purpose of this Non-Employee Director Compensation Policy (this “Policy”) of Karyopharm Therapeutics Inc. (the “Company”) is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors and reflect the substantial tim

As filed with the Securities and Exchange Commission on August 5, 2021

As filed with the Securities and Exchange Commission on August 5, 2021 Registration No.

As filed with the Securities and Exchange Commission on August 5, 2021

Table of Contents As filed with the Securities and Exchange Commission on August 5, 2021 Registration No.